1. Rahul Misra, Mohita Upadhyay, Vivekanandan Perumal, Sanat Mohanty.  In vitro control release, cytotoxicity assessment and cellular uptake of methotrexate loaded liquid-crystalline folate nanocarrier. Biomedicine and Pharmacotherapy. [In press].
  2. Upadhyay M, Sharma N, Vivekanandan P*. Systematic CpT(ApG) depletion and CpG excess are unique genomic signatures of large DNA viruses infecting invertebrates. PLoS One (in press) (*Corresponding author). Impact factor 3.53
  3. Samal J, Kandpal M, Vivekanandan P*. A simple and rapid method for the quantitation of secreted hepatitis B virions in cell culture models. Indian J Med Microbiol (in press) (*Corresponding author). Impact factor 1.04
  4. Upadhyay M, Samal J, Kandpal M, Vasaikar S, Biswas B, Gomes J, Vivekanandan P*. CpG dinucleotide frequencies reveal the role of host methylation capabilities in parvovirus evolution. J Virol. 2013 Dec; 87(24):13816-13824. (*Corresponding author). Impact factor 5.0
  5. Upadhyay M, Samal J, Kandpal M, Singh OV, Vivekanandan P*. The Warburg effect: insights from the past decade. Pharmacol Ther. 2013 Mar; 137(3):318-330. (*Corresponding author). Impact factor 7.5
  6. Samal J, Kandpal M, Vivekanandan P*. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev. 2012; 25(1):142-163.  (*Corresponding author). Impact factor 17.1
  7. Ross HM, Daniel HD, Vivekanandan P, Kannangai R, Yeh MM, Wu TT, Makhlouf HR, Torbenson M. Fibrolamellar carcinomas are positive for CD68. Mod Pathol. 2010. Impact factor 4.4
  8. Vivekanandan P*, Singh OV. Molecular methods in the diagnosis and management of chronic hepatitis B. Expert Rev Mol Diagn. 2010; 10 (7):921-35. (*Corresponding author). Impact factor 3.7
  9. Vivekanandan P, Torbenson M, Ramakrishna B. Hepatitis B Virus-Associated Hepatocellular Carcinoma from India: Role of Viral Genotype and Mutations in CTNNB1 (Beta-Catenin) and TP53 Genes. J Gastrointest Cancer. 2010.  Impact factor 0.8
  10. Vivekanandan P, Daniel H, Yeh MM, Torbenson M.    Mitochondrial mutations in hepatocellular carcinomas and fibrolamellar carcinomas. Mod Pathol. 2010; 23(6):790-798. Impact factor 4.4
  11. Lam M, Torbenson M, Yeh MM, Vivekanandan P, Ferrell L.  HFE mutations in alpha-1-antitrypsin deficiency: an examination of cirrhotic explants.  Mod Pathol. 2010. 23(5):637-643. Impact factor 4.4
  12. Vivekanandan P, Daniel HD, Kannangai R, Martinez-Murillo F, Torbenson M. Hepatitis B Viral Replication Induces Methylation of Both Host and Viral DNA. J Virol.2010 Feb 10. . 2010; 84(9):4321-4329. Impact factor 5.2
  13. Balagopal A, Ray SC, de Oca RM, Sutcliffe CG, Vivekanandan P, Higgins Y, Mehta SH, Moore RD,  Sulkowski MS, Thomas DL, Torbenson MS.  Kupffer Cells are depleted with HIV Immunodeficiency and partially recovered with antiretroviral Immune reconstitution. AIDS. 2009; 23: 2397-2404. Impact factor 5.7
  14. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, Mendell JR, Mendell JT. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell.  2009; 137: 1005-1017. Impact factor 31.1
  15. Fenton H, Torbenson M, Vivekanandan P, Yeh MM, Hart J, Ferrell L. Marked iron in liver explants in the absence of major hereditary hemochromatosis gene defects: a risk factor for cardiac failure. Transplantation 2009; 87: 1256-1260. Impact factor 3.5
  16. Vivekanandan P, Thomas D, Torbenson M. Methylation Regulates Hepatitis B Viral Protein Expression. J Infect Dis.  2009; 199: 1286-1291. Impact factor 5.9
  17. Selaru FM, Olaru AV, Kan T, David S, Cheng Y, Mori Y, Yang J, Paun B, Jin Z, Agarwal R, Hamilton JP, Abraham J, Georgiades C, Alvarez H, Vivekanandan P, Yu W, Maitra A, Torbenson M, Thuluvath PJ, Gores GJ, Larusso NF, Hruban R, Meltzer SJ. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology. 2009; 49: 1595-1601. Impact factor 10.8
  18. Vivekanandan P, Kannangai R, Ray SC, Thomas DL, Torbenson M. Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin Infect Dis. 2008; 46:1227-1236.  Impact factor 8.2
  19. Daniels JA, Torbenson M, Vivekanandan P, Anders RA, Boitnott JK. Hepatitis in common variable immunodeficiency. Hum Pathol. 2008; 40: 484-488.  Impact factor 3.0
  20. Vivekanandan P,  Bissett S,  Ijaz S,  Teo CG,  Sridharan G,  Raghuraman S,  Daniel HD,  Kavitha ML,  Daniel D,  Chandy GM,  Abraham P. Correlation between hepatitis B genotypes, 1896 precore mutation, virus loads and liver dysfunction in an Indian population. Indian J Gastroenterol. 2008: 27(4):142-147 Impact factor 0.6
  21. Chaerkady R, Harsha HC, Nalli A, Gucek M, Vivekanandan P, Akhtar J, Cole RN, Simmers J, Schulick RD, Singh S, Torbenson M, Pandey A, Thuluvath PJ. A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma. J Proteome Res. 2008 Oct; 7(10):4289-98. Impact factor 5.1
  22. Chaerkady R, Thuluvath PJ, Kim MS, Nalli A, Vivekanandan P, Simmers J, Torbenson M, Pandey A. O Labeling for a Quantitative Proteomic Analysis of Glycoproteins in Hepatocellular Carcinoma. Clin Proteomics. 2008; 4:137-55.  Impact factor: 1.2
  23. Vivekanandan P,  Micchelli ST,  Torbenson M. Anterior gradient-2 is overexpressed by fibrolamellar carcinomas. Hum Pathol. 2008; 21: 491-497. Impact factor 3.0
  24. Vivekanandan P, Torbenson M. Low frequency of Helicobacter DNA in benign and malignant liver tissues from Baltimore, United States. Hum Pathol. 2008; 39:213-216. Impact factor 2.806
  25. Vivekanandan P, Thomas D, Torbenson M. Hepatitis B viral DNA is methylated in liver tissues. J Viral Hepat. 2008; 15:103-107. Impact factor 3.4
  26. Vivekanandan P, Daniel HD, Raghuraman S, Daniel D, Shaji RV, Sridharan G, Chandy G, et al. Novel digestion patterns with hepatitis B virus strains from the Indian subcontinent detected using restriction fragment length polymorphism. Indian J Med Microbiol. 2008; 26:96-97. Impact factor 1.04
  27. Vivekanandan P, Torbenson M. Epigenetic instability is rare in fibrolamellar carcinomas but common in viral-associated hepatocellular carcinomas. Mod Pathol. 2008; 21: 670-675. Impact factor 4.4
  28. Vivekanandan P, Singh OV. High-dimensional biology to comprehend hepatocellular carcinoma. Expert Rev Proteomics.  2008; 5: 45-60. Impact factor 3.6
  29. Micchelli ST, Vivekanandan P, Boitnott JK, Pawlik TM, Choti MA, Torbenson M. Malignant transformation of hepatic adenomas. Mod Pathol 2008; 21:491-497. Impact factor 4.4
  30. Daniel HD, Vivekanandan P, Raghuraman S, Sridharan G, Chandy GM, Abraham P. Significance of the hepatitis C virus (HCV) core antigen as an alternative plasma marker of active HCV infection. Indian J Med Microbiol 2007; 25:37-42. Impact factor 1.04
  31. Kannangai R, Vivekanandan P, Netski D, Mehta S, Kirk GD, Thomas DL, Torbenson M. Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection. J Clin Virol 2007; 39:101-105. Impact factor 3.446
  32. Kannangai R, Vivekanandan P, Martinez-Murillo F, Choti M, Torbenson M. Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways. Hum Pathol 2007; 38:639-644. Impact factor 2.806
  33. Perumal V, Wang J, Thuluvath P, Choti M, Torbenson M. Hepatitis C and hepatitis B nucleic acids are present in intrahepatic cholangiocarcinomas from the United States. Hum Pathol 2006; 37:1211-1216. Impact factor 2.806
  34.  Sicklick JK, Li YX, Jayaraman A, Kannangai R, Qi Y, Vivekanandan P, Ludlow JW, et al. Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis 2006; 27:748-757.  Impact factor 5.266
  35. Daniel HD, Abraham P, Raghuraman S, Vivekanandan P, Subramaniam T, Sridharan G. Evaluation of a rapid assay as an alternative to conventional enzyme immunoassays for detection of hepatitis C virus-specific antibodies. J Clin Microbiol 2005; 43:1977-1978.  Impact factor 4.232   
  36. Vivekanandan P, Abraham P, Sridharan G, Chandy G, Shaji RV, Daniel D, Raghuraman S, et al. High frequency of the 1896 precore mutation in patients and blood donors with hepatitis B virus infection from the Indian subcontinent. Mol Diagn 2004; 8: 51-56.  
  37. Vivekanandan P, Abraham P, Sridharan G, Chandy G, Daniel D, Raghuraman S, Daniel HD, et al. Distribution of hepatitis B virus genotypes in blood donors and chronically infected patients in a tertiary care hospital in southern India. Clin Infect Dis 2004; 38:e81-86. Impact factor 9.416
  38. Perumal V, Mathai E, Jose J, Gupta S. Prevalence of Chlamydia pneumoniae IgG antibodies in patients with coronary artery disease: a report from an Indian population. Indian Heart J 2003; 55: 667.


  1. Portable device and chip for immuno-magnetic capture and enrichment of Biomarker (Co-inventor)

  2. On chip immunocapture and fluorescent detection of rare cells in large sample volume (Co-inventor)

Funding (as principal investigator)

  1. Role of defective hepatitis B virus (dHBV) particles in modulating the replication of hepatitis B virus (DBT)

  2. The Biological role of hepatitis B “e” antigen in modulating hepatitis B replication (ICMR)

  3. The role of hepatitis B “e” antigen in the pathogenesis of HBV-related hepatocellular carcinoma (ICMR)

Honors /Awards

  1. American Society for Microbiology(ASM) travel teacher award for an oral presentation at Colorado State University, Fort Collins, CO.

  2. Outstanding young faculty fellowship at IIT Delhi. (2011-2013)

  3. British council higher education program- training at Health Protection Agency London, UK.

  4. IAMM Prize for Best Published paper in Virology in the year 2006     

  5. Hepatitis B Foundation Travel grant - International meeting on HBV, La Jolla, California, USA.  

  6. J Mitra Memorial award for the best scientific contribution in Indian Journal of Gastroenterology.

  7. Travel grant for an oral presentation at the young investigator meet Boston, MA, USA.